Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 9/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486471 | 0.93 | MAPK8 (0.41) | KMT2AMEN1RETMAPK8MAPT | |
| SCHEMBL19481966 | 0.93 | MAPK8 (0.41) | KMT2AMEN1RETMAPK8MAPT | |
| SCHEMBL19481880 | 0.90 | KMT2A (0.39) | KMT2AMEN1RETMAPTPKM | |
| SCHEMBL19481873 | 0.90 | KMT2A (0.39) | KMT2AMEN1RETMAPTPKM | |
| SCHEMBL19481918 | 0.89 | MEN1 (0.37) | KMT2AMEN1RETMAPT | |
| SCHEMBL19481748 | 0.89 | KMT2A (0.44) | KMT2AMEN1MAPK8MAPTPKM | |
| SCHEMBL19481843 | 0.89 | RET (0.38) | KMT2AMEN1RETMAPT | |
| SCHEMBL20820709 | 0.89 | RET (0.38) | KMT2AMEN1RETMAPT | |
| SCHEMBL19481842 | 0.89 | RET (0.38) | KMT2AMEN1RETMAPT | |
| SCHEMBL19486807 | 0.89 | RET (0.38) | RETMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | KMT2A 2335/4885MEN1 2451/4885RET 50/4885 |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | KMT2A 2335/4885MEN1 2451/4885RET 50/4885 |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | KMT2A 2335/4885MEN1 2451/4885RET 50/4885 |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | KMT2A 3270/4885MEN1 2076/4885RET 56/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | KMT2A 2335/4885MEN1 2451/4885RET 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.